Literature DB >> 16319054

Induction of cardiac hypertrophy by a controlled reproducible sutureless aortocaval shunt in the mouse.

Tony Karram1, Aaron Hoffman, Bishara Bishara, Sergey Brodsky, Eliahu Golomb, Joseph Winaver, Zaid Abassi.   

Abstract

Much of the understanding about the pathophysiological responses to chronic cardiac overload has been gained by the use of rat and dog models of aortocaval fistula (ACF). The use of a similar model in genetically manipulated mice may further elucidate the molecular mechanisms in these responses. The only reports about ACF in mice to date have applied a needle puncture to create the ACF, which may result in an uncontrolled and irreproducible size of the shunt, and require several weeks to induce the characteristic cardiac changes. In order to obtain a more consistent approach to characterize this mode of cardiac hyperfunction, we present a surgical murine model of ACF that results in rapid progression of the typical systemic and cardiac changes. A sutureless side-to-side infrarenal surgical anastomosis of 0.6-0.8 mm in diameter was created between the abdominal aorta and inferior vena cava in ICR (Institute of Cancer Research) mice. Six to 7 days later, significant cardiac hypertrophy developed. The heart/body weight ratio increased from 0.45 +/- 0.02% in control mice to 0.77 +/- 0.03% in mice with ACF (p < .003). The dry heart weight ratio increased from 0.099 +/- 0.0033% to 0.13 +/- 0.008% (p < .006). The ACF dramatically induced the atrial and ventricular expression of atrial natriuretic factor mRNA, and increased the total cardiac content of endothelin-1 (162.5 +/- 50.6 vs. 83.9 +/- 9.0 pg). Mean arterial pressure in anesthetized mice with ACF decreased from 69.8 +/- 4.9 to 54.8 +/- 5.5 mm Hg (p < .025). Urinary sodium excretion returned to preoperative levels several days following surgery. These results demonstrate that cardiac hypertrophy could be rapidly and reproducibly achieved in mice by the placement of a surgical ACF. This model, when applied in genetically manipulated mice, may be a valuable tool for functional genomic studies about the pathogenesis of cardiac hypertrophy and heart failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319054     DOI: 10.1080/08941930500328839

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  5 in total

1.  Technical aspects of the mouse aortocaval fistula.

Authors:  Kota Yamamoto; Xin Li; Chang Shu; Tetsuro Miyata; Alan Dardik
Journal:  J Vis Exp       Date:  2013-07-11       Impact factor: 1.355

2.  Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.

Authors:  Kevin J Morine; Xiaoying Qiao; Vikram Paruchuri; Mark J Aronovitz; Emily E Mackey; Lyanne Buiten; Jonathan Levine; Keshan Ughreja; Prerna Nepali; Robert M Blanton; Richard H Karas; S Paul Oh; Navin K Kapur
Journal:  Heart Vessels       Date:  2017-02-17       Impact factor: 2.037

3.  Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium.

Authors:  Takuya Hashimoto; Kota Yamamoto; Trenton Foster; Hualong Bai; Kunihiro Shigematsu; Alan Dardik
Journal:  J Vis Exp       Date:  2016-03-04       Impact factor: 1.355

4.  The mouse aortocaval fistula recapitulates human arteriovenous fistula maturation.

Authors:  Kota Yamamoto; Clinton D Protack; Masayuki Tsuneki; Michael R Hall; Daniel J Wong; Daniel Y Lu; Roland Assi; Willis T Williams; Nirvana Sadaghianloo; Hualong Bai; Tetsuro Miyata; Joseph A Madri; Alan Dardik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-04       Impact factor: 4.733

Review 5.  Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.

Authors:  Zaid Abassi; Ilia Goltsman; Tony Karram; Joseph Winaver; Aaron Hoffman
Journal:  J Biomed Biotechnol       Date:  2011-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.